NF-E2-related factor 2 (NRF2) is a key regulator of oxidative stress and is normally sequestered in the cytoplasm by the Kelch-like ECH associated protein 1 (KEAP1). Covalent modification of reactive cysteines on KEAP1 by electrophiles alters the NRF2–KEAP1 interaction, resulting in NRF2 accumulation and pathway activation. Although covalent small-molecule inhibitors of KEAP1 have been described, Bollong et al. sought find an alternative means of activating NRF2, identifying the nonelectrophilic small molecule CBR-470-1 from a high-throughput screen. Target identification studies revealed that CBR-470-1 directly inhibits the glycolytic enzyme phosphoglycerate kinase 1 (PGK1), resulting in accumulation of metabolites including methylglyoxal (MGO). Interestingly, CBR-470-1 treatment or PGK1 knockdown resulted in the appearance of a high-molecular-mass form of KEAP1 that was associated with NRF2 activation and dependent on MGO. Finally, direct interaction of KEAP1 with MGO resulted in a new post-translational modification: a methylimidazole cross-link between C151 and R135 of KEAP1. Overall, these findings reveal a unique interplay between glucose metabolism, KEAP1 function and the cellular antioxidant response.
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Miura, G. Playing KEAP1-away. Nat Chem Biol 15, 2 (2019). https://doi.org/10.1038/s41589-018-0197-y
Published:
Issue Date:
DOI: https://doi.org/10.1038/s41589-018-0197-y
This article is cited by
-
PGK1 depletion activates Nrf2 signaling to protect human osteoblasts from dexamethasone
Cell Death & Disease (2019)